SGLT2 inhibitors work in the early proximal convoluted tubule, the very first stretch of tubing that filtered fluid enters after leaving the glomerulus. Specifically, the SGLT2 protein sits on the brush border membrane of cells lining this segment, facing the fluid flowing through the tube. This location is critical because it’s where the vast majority of filtered glucose gets recaptured before it can travel deeper into the kidney.
The Proximal Tubule and Glucose Recovery
Every time blood passes through the kidney’s filtering unit (the glomerulus), glucose freely crosses into the filtrate along with water, salts, and waste products. In a healthy kidney, virtually all of that glucose gets pulled back into the bloodstream before urine forms. Two transporters handle this job: SGLT2 and SGLT1.
SGLT2 sits in the early proximal convoluted tubule and reclaims about 97% of filtered glucose under normal conditions. SGLT1, located further downstream in the late proximal tubule, picks up the remaining 3%. Immunohistochemistry studies confirm that SGLT2 staining appears only on the apical brush border of early proximal tubule cells, with no signal detected in late proximal segments, straight tubule portions, or any downstream part of the nephron.
Both transporters work by coupling glucose transport to sodium. Each time an SGLT2 transporter moves a glucose molecule out of the filtrate and into the tubule cell, it drags a sodium ion along with it. That sodium then gets pumped out the other side of the cell by a sodium-potassium pump, which requires energy in the form of ATP. This detail matters because it connects glucose reabsorption directly to the kidney’s oxygen and energy demands.
How SGLT2 Inhibitors Block This Process
SGLT2 inhibitors bind to the SGLT2 transporter and prevent it from pulling glucose (and its paired sodium) out of the filtrate. The glucose that would normally be reabsorbed instead continues flowing through the tubule and eventually leaves the body in urine. This is why people taking these medications notice higher urine glucose levels.
Blocking SGLT2 doesn’t eliminate all glucose reabsorption, though. When SGLT2 is shut down, SGLT1 ramps up its activity further along the tubule. The net result is that SGLT2 inhibitors actually block only about 30% to 50% of glucose reabsorption, not the full 97% you might expect. That compensatory response from SGLT1 is one reason these drugs cause meaningful but manageable glucose loss rather than dangerously stripping the body of its fuel.
The Downstream Effect on Filtering Pressure
The most consequential thing SGLT2 inhibitors do may not be about glucose at all. Because they also block sodium reabsorption in the proximal tubule, more sodium arrives at a sensor called the macula densa, a cluster of specialized cells located where the tubule loops back near its own glomerulus. The macula densa detects this sodium increase and triggers a response called tubuloglomerular feedback.
Here’s what that looks like: the macula densa releases signaling molecules that cause the afferent arteriole (the small blood vessel feeding the glomerulus) to constrict. This constriction reduces the pressure inside the glomerulus, lowering the filtration rate. In a healthy kidney this might sound counterproductive, but in conditions like diabetes, the glomerulus is often under abnormally high pressure. Diabetic kidneys tend to overexpress SGLT2, increasing sodium reabsorption by as much as 36%. The macula densa misreads this as low circulating volume and relaxes the afferent arteriole, driving glomerular pressure up. Over time, that hyperfiltration damages the delicate filtering membrane.
SGLT2 inhibitors reverse this cycle. By restoring normal sodium delivery to the macula densa, they bring afferent arteriole tone back toward normal and relieve the excess pressure. The mechanism is similar in concept to how older blood pressure medications protect the kidney by relaxing the efferent arteriole (the vessel leaving the glomerulus), but SGLT2 inhibitors achieve their pressure reduction from the opposite side of the equation.
Reducing Oxygen Stress in the Kidney
Reabsorbing glucose is expensive work for proximal tubule cells. Every sodium ion that hitches a ride with glucose must eventually be expelled by sodium-potassium pumps, and those pumps burn through ATP and consume oxygen. In diabetic kidneys, where glucose reabsorption is ramped up, the proximal tubule’s oxygen demand outstrips its supply, creating a state of chronic low-oxygen stress (hypoxia).
SGLT2 inhibitors reduce this workload directly. By stopping glucose and sodium from entering proximal tubule cells in the first place, they lower the activity of sodium-potassium pumps and cut the cortex’s active oxygen consumption by roughly 30%. Animal studies have shown that this relief is enough to reverse markers of hypoxia in proximal tubule cells and reduce damage to the surrounding tissue. In practical terms, the kidney’s most metabolically active cells get a break from being overworked.
What This Means for Kidney Protection
The combination of lower glomerular pressure, reduced oxygen stress, and decreased hyperfiltration translates into measurable kidney protection in clinical trials. In the CREDENCE trial, canagliflozin reduced the combined risk of kidney failure, doubling of creatinine, or death from kidney or cardiovascular causes by 30% compared to placebo. The DAPA-CKD trial found even larger benefits with dapagliflozin: a 39% reduction in the risk of significant kidney function decline, kidney failure, or death from kidney or cardiovascular causes. These benefits held in people with and without diabetes.
One pattern that initially concerned clinicians is a small, early dip in estimated kidney filtration rate (eGFR) when someone starts an SGLT2 inhibitor. This dip reflects the intended reduction in glomerular pressure and typically stabilizes within a few weeks. Over the longer term, the rate of kidney function decline slows considerably compared to people not taking the medication, which is why the early dip is now seen as a sign the drug is working rather than a cause for alarm.
SGLT2 inhibitors also reduce albumin in the urine, a key marker of kidney damage. By lowering the pressure forcing proteins through the glomerular membrane, they address one of the earliest visible signs of progressive kidney disease.
Why Extra Urine Glucose Causes Side Effects
The same mechanism that protects the kidneys creates a tradeoff. Glucose that stays in the urine passes through the bladder and urethra, creating an environment where naturally present microorganisms can thrive. This is why genital yeast infections are the most common side effect of SGLT2 inhibitors, particularly in women. The elevated glucose in urine essentially feeds commensal fungi that would otherwise remain in check. Urinary tract infections can also occur through a similar mechanism, though the risk increase is smaller than for yeast infections. Staying well hydrated and maintaining good hygiene helps reduce this risk in practice.